Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Efficacy/ safety for the combination of anti-IgE (Omalizumab) and specific immunotherapy
(Depigoid) in patients with not adequately controlled seasonal allergic asthma and comorbid
seasonal allergic rhinoconjunctivitis.